Israel Steps Closer to Cannabis Legalization


Ryan Allway

August 12th, 2020

App, Exclusive, Top Story


Israel could become the next country to legalize adult-use cannabis after lawmakers gave preliminary approval to two bills calling for the decriminalization of cannabis and the regulation of its sale for recreational and medical use.

Let’s take a closer look at the move and what it means for public companies operating in the country, including Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF)—the only Israeli pure-play opportunity in the space.

Legalization on the Horizon

The Israeli government’s approval of two preliminary cannabis bills would decriminalize the possession and use of small quantities of cannabis, as well as create a regulatory framework governing the sale of adult-use and medical cannabis in the country. While the discussions remain early-stage, it could mirror that of Canada or other legal countries.

Israel has a burgeoning medical cannabis industry already that has more than 50,000 authorized users and that figure is rapidly growing. At the same time, the country has some of the highest per capita cannabis usage rates in the world at nearly one-third of people between the ages of 18 and 65—creating an enormous market opportunity.

Click here to learn more about being an early investor in the Israeli cannabis market

In addition to its legalization efforts, Israel has long been a leader in cannabis research and development. The country became the first country in the world to allow medical research and cultivation back in 2007, while THC and CBD cannabinoid structures were originally discovered at Hebrew University of Jerusalem.

The Israeli Cabinet approved the export of medical cannabis back in 2019 and the government gave the final go-ahead earlier this year. The move could open the door to exports to the European Union, which is located nearby and represents a massive and underserved market for medical cannabis and CBD products.

Capitalizing on the Market

There are several public and private companies targeting the Israeli cannabis industry, but few of them are pure-plays that trade on North American exchanges.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) has an expected annual capacity of more than 23,000 kilograms of dried cannabis at its Cannisra farm and with Israel’s favorable climate, management anticipates becoming a low-cost cannabis producer with costs of just $0.40 per gram—translating to attractive margins.

Click the image below to view a brief overview of the cannabis opportunity in Israel 

Additionally, in the Hefer Valley region, the company’s joint venture farm, Cannation Ltd., is nearing the completion of phase one construction and already has signed an offtake agreement with Israeli licensed producer Focus Medical Herbs Ltd. The property contains a 55,000 sq. ft. greenhouse that’s complete and awaiting final security inspection and a 110,000 sq. ft. facility for use as expansion.

Click here to learn more about being an early investor in the Israeli cannabis market

“From our ongoing development efforts at our initial Cannisra Holdings project, to our exciting advancements in the Hefer Valley, we’ve mapped out an integrated package of properties with a multi-greenhouse strategy which includes a network of important partners and stakeholders across Israel and Europe,” said CEO Darryl Jones.

Looking Ahead

Israel is rapidly progressing toward domestic legalization and the export of medical cannabis to the undersupplied European Union. Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is well positioned to capitalize on these dynamics with its various ongoing projects and agreements that are close to reaching a commercialization point.

For more information, visit the company’s website at www.isracann.com

Click here to learn more about being an early investor in the Israeli cannabis market

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading